Literature DB >> 17368113

Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH).

J Suntharalingam1, R J Hughes, K Goldsmith, N Doughty, P George, M Toshner, K K Sheares, J Pepke-Zaba.   

Abstract

INTRODUCTION: Although surgery is the treatment of choice for CTEPH, it is not appropriate for patients with surgically inaccessible distal disease. These patients are traditionally managed supportively, but may benefit from newer, more specific vasoactive therapies. This study examines the acute haemodynamic responses to inhaled nitric oxide (iNO) and intravenous sildenafil in this patient population.
METHODS: Nine patients with de novo distal CTEPH and nine with persistent pulmonary hypertension post-pulmonary endarterectomy (PEA) were enrolled. At right heart catheterisation, following baseline haemodynamic measurements, iNO was administered at 20 ppm for 10 min. Following repeat measurements, iNO was discontinued with a subsequent washout period of 10 min. Sildenafil was then administered intravenously at two doses, to achieve plasma levels equivalent to 25 mg and 50 mg orally, with further measurements obtained at the end of each infusion.
RESULTS: Significant reductions in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) were demonstrated following both iNO (-4.3 mm Hg or -10.3% p=0.001 and -101 dyn/s/cm(5) or -15.6% p<0.001) and sildenafil (-7.4 mm Hg or -16.9% p<0.001 and -188.8 dyn/s/cm(5) or -25.1% p<0.001). Individual mPAP and cardiac output (CO) responses to iNO and sildenafil correlated well, but haemodynamic changes following sildenafil were consistently more marked. There was, however, no difference in effect between the two doses of sildenafil. Although sildenafil caused significant reductions in systemic vascular resistance, the net haemodynamic effect of sildenafil remained pulmonary selective. Subgroup analysis suggested that post-PEA patients were more responsive to both iNO and sildenafil than de novo patients. DISCUSSION: Although all but one patient failed to fulfil the formal haemodynamic response criteria typically used in idiopathic pulmonary arterial hypertension (IPAH), subjects displayed significant acute responses to both iNO and sildenafil suggesting that increased vascular tone forms an important component of distal CTEPH. It is possible that these acute haemodynamic responses may translate to improved clinical outcomes, and thus further long term trials of sildenafil in distal CTEPH are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368113     DOI: 10.1016/j.vph.2007.01.008

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  9 in total

1.  Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.

Authors:  Jean-Luc Vachiery; Sandrine Huez; Hunter Gillies; Gary Layton; Naoto Hayashi; Xiang Gao; Robert Naeije
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

2.  Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension.

Authors:  Katrin Milger; Janine F Felix; Robert Voswinckel; Natascha Sommer; Oscar H Franco; Friedrich Grimminger; Frank Reichenberger; Werner Seeger; Hossein A Ghofrani; Henning Gall
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

3.  Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension.

Authors:  Neda Behzadnia; Katayoun Najafizadeh; Babak Sharif-Kashani; Davoud Oulad Dameshghi; Payman Shahabi
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

4.  Acute effects of sildenafil and dobutamine in the hypertrophic and failing right heart in vivo.

Authors:  Asger Andersen; Jan M Nielsen; Sivagowry Rasalingam; Erik Sloth; Jens Erik Nielsen-Kudsk
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

5.  Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.

Authors:  Stephen J Halliday; Anna R Hemnes; Ivan M Robbins; Meredith E Pugh; David X Zhao; Robert N Piana; Pete P Fong; Evan L Brittain
Journal:  J Heart Lung Transplant       Date:  2014-11-04       Impact factor: 10.247

6.  Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Authors:  Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba
Journal:  J Heart Lung Transplant       Date:  2010-03-15       Impact factor: 10.247

7.  Inflammatory response and pneumocyte apoptosis during lung ischemia-reperfusion injury in an experimental pulmonary thromboembolism model.

Authors:  Chaosheng Deng; Zhenguo Zhai; Dawen Wu; Qichang Lin; Yuanhua Yang; Minxia Yang; Haibo Ding; Xiaoming Cao; Qiaoxian Zhang; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

8.  Beneficial effects of inhaled NO on apoptotic pneumocytes in pulmonary thromboembolism model.

Authors:  Chaosheng Deng; Minxia Yang; Qichang Lin; Yuanhua Yang; Zhenguo Zhai; Kaixiong Liu; Haibo Ding; Xiaoming Cao; Zhihua Huang; Lina Zhang; Jianming Zhao
Journal:  Theor Biol Med Model       Date:  2014-08-10       Impact factor: 2.432

Review 9.  Pulmonary Hypertension in Intensive Care Units: An Updated Review.

Authors:  Armin Nowroozpoor; Majid Malekmohammad; Seyyed Reza Seyyedi; Seyed Mohammadreza Hashemian
Journal:  Tanaffos       Date:  2019-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.